This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neoplasms  • Dermatology, Other  • Alert me on articles by topic

Arch Dermatol. 2000;136:1145-1148.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma
Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid AC
Cancer. 1999;86:2252-2258.

More than 44,000 new cases of melanoma are detected annually in the United States, and the number is steadily increasing. The majority of patients are treated with surgical excision and may, in addition, undergo sentinel node mapping, lymph node dissection, and adjunctive treatment. The purpose of this study was to develop rational, evidence-based guidelines for following up patients with 1983 American Joint Committee on Cancer stage I (<1.5 mm thick), II (localized disease >1.5 mm thick), and III (local nodal or in-transit metastases) melanoma.

The study was a retrospective review of charts of 373 patients who were followed up according to the surveillance protocol at the Yale Melanoma Unit, New Haven, Conn, between . . . [Full Text of this Article]

Editor's Comment